1. Potential adverse events associated with interventions for prevention of post‐operative atrial fibrillation.

Intervention	Potential Adverse Events (% incidence)
Pharmacological Interventions
Amiodarone	‐ Serum creatinine increase (93%) ‐ Hypotension (16%) ‐ Phlebitis of administration site (not defined) ‐ Ventricular arrhythmias (2%‐5%) ‐ Hepatotoxicity (3%‐20%)
Beta‐blockers	‐ Bradycardia (3%) ‐ Hypotension (1%) ‐ Exacerbation of decompensated congestive heart failure (< 1%) ‐ Bronchospasm (rare)
Sotalol	‐ Dyspnea (21%) ‐ Bradycardia (16%) ‐ Hypotension (6%) ‐ Torsades de pointes or new ventricular arrhythmia (4% in patients with supraventricular arrhythmia)
Magnesium	‐ Hypotension (rare)
Non‐Pharmacological Interventions
Atrial Pacing	‐ Atrial irritability (not defined)
Posterior Pericardiotomy	‐ Not defined